Premium Parent, LLC acquires Premier, Inc. (2025)

Deal facts

Buyer: Premium Parent, LLC
Target: Premier, Inc.
Deal value: Not disclosed
Announced: 21 September 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

25 Nov 2025CompletedClosed
Premium Parent, LLC completes acquisition of Premier, Inc.
Introductory Note On September 21, 2025, Premier, Inc. (“ Premier ” or the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Premium Parent, LLC, a Delaware limited liability company (“ Parent ”), and Premium Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”). The Merger Agreement provides tha
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Premier, Inc by Premium Parent, LLC. This transaction moves a major US healthcare entity from public markets into private ownership. The deal structure is straightforward: a cash offer that removes the target from public listing. There is no public valuation attached to this announcement, yet the mechanism itself speaks volumes. When a buyer elects to take a company private using cash, they are betting on long-term operational freedom rather than quarterly earnings pressure. This is a decisive shift in strategy for the sector.

The choice of a going-private route often reflects a desire to restructure without the noise of public scrutiny. For the SME founder reading this, the lesson is about timing and structure. Public markets demand transparency that can sometimes stifle necessary, painful changes. A private buyer can absorb short-term disruption to build long-term value. The cash consideration confirms that the buyer has secured the liquidity to execute immediately. This removes the uncertainty of stock-based deals and eliminates the need for shareholder approval battles that often derail complex transactions. It is a clean break from public reporting cycles.

Regulatory clearance in the US healthcare sector is never trivial. Even with a cash deal, competition authorities will scrutinise the combined entity to ensure it does not stifle market competition. The buyer must navigate anti-trust thresholds and potential change-of-control covenants embedded in existing debt or contracts. These are not mere formalities; they are concrete hurdles that can delay or alter the final terms. The speed of completion suggests that the parties have already addressed these regulatory and commercial contingencies. This efficiency is a hallmark of well-prepared private equity or strategic buyers who understand the stakes.

Do not wait for a public market rally to consider your exit options if your business model requires significant restructuring. This week, review your current debt covenants and identify any change-of-control clauses that could trigger early repayment or restrict a sale. Understanding these constraints now will determine whether you can execute a clean, cash-based exit when the right private buyer appears.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from Premium Parent, LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history